Teva’s Partner Antares Swallowed Up By Halozyme In $960m Deal
Teva/Antares Alliance Offers Gx EpiPen; US Forteo Rival Under Development
Executive Summary
For just shy of $1bn, Halozyme Therapeutics is set to acquire drug development and injectable technology specialist Antares Pharma, providing it with a portfolio and pipeline of Teva products through a long-term partnership.
You may also be interested in...
Standalone Sandoz And Biocon’s Biosimilars: 2022’s Biggest Deals
The acquisition and consolidation mania that gripped industry in the middle half of the last decade may seem like a distant dream but players continued to spend cash where it could be justified in 2022, while raising much-needed capital to fund their endeavors.
Strides Says Forsteo Biosimilar ‘Significant Product’, Seeks New Minority Investor In Stelis
Strides sees Kauliv, a biosimilar to Eli Lilly’s Forsteo, as a ‘significant’ but ‘not a massive product’ as it prepares to register it in multiple countries post a positive opinion from EMA. Meanwhile, more clarity on fund raising for Stelis is expected by March 2023 even as the regulatory timeline for a COVID-19 vaccine from Akston is extended by 2-3 months
Sun’s Teriparatide And Multiple Aubagio Rivals Among CHMP Recommendations
Sun’s rival to Forsteo, Accord and Mylan’s versions of Aubagio and Accord’s Nexavar generic were all endorsed by the European Medicines Agency at the CHMP’s September meeting.